Pune, India -- (SBWIRE) -- 05/17/2018 -- Global Carcinoid Syndrome Management Market - Key Players
Key players profiled in the report are:
Novartis International AG (Sandoz) (Switzerland)
Pharmascience Inc. (Canada)
Omega Laboratories Ltd. (Canada)
Teva Pharmaceutical Industries Ltd. (Israel)
Mylan N.V. (USA)
Ipsen Biopharmaceuticals Inc.(US)
Sirtex Medical Limited (Australia)
BTG International Ltd. (UK)
Wockhardt Ltd.
Sun Pharmaceutical Industries Limited (India)
Global Carcinoid Syndrome Management Market - Overview
The Global Carcinoid Syndrome Management Market is growing with the sound pace. According to a recent study report published by the Market Research Future, the Global Carcinoid Syndrome Management is booming and expected to gain prominence over the forecast period and is projected to grow a sound pace. The market is projected to demonstrate a sound growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017-2022).
Carcinoid syndrome includes the signs and symptoms of flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. Palliative and supportive care is often required for the management or treatment of carcinoid syndrome. Drug therapy and surgical removal of carcinoid tumor are the major management procedures for carcinoid syndrome. Increasing incidence of hormonal disorders, and growing smoking habits are the major drivers for the market growth. However, no availability of drugs approved to manage carcinoid syndrome may restrain the market growth during the forecast period.
Global Carcinoid Syndrome Management Market - Intended Audience
Global carcinoid syndrome management or treatment device manufacturers & suppliers
Contract research organizations (CROs)
Research and development (R&D) companies
Government research laboratories
Independent research laboratories
Government and independent regulatory authorities
Market research and consulting service providers
Academic institutes and universities
Global Carcinoid Syndrome Management Market - Competitive Analysis
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
In November-2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD).
Click to Get Sample Report @ https://www.marketresearchfuture.com/sample_request/2843 .
In August-2016, Teva Pharmaceutical Industries Ltd. and Allergan plc. Announced that Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan's generics business. This strategic acquisition brought together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks and cultures.
In January-2017, Ipsen entered into a definitive agreement and acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen gained exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan.
Global Carcinoid Syndrome Management Market - Regional Analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Get Unbelievable Discount on Report @ https://www.marketresearchfuture.com/check-discount/2843.
Global Carcinoid Syndrome Management Market - Segments
The global carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
Major Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
List of Tables
Table 1 Global Carcinoid Syndrome Management Market, By Organs Affected, 2017-2022 (USD Million)
Table 2 Global Carcinoid Syndrome Management Market, By Treatment Type, 2017-2022 (USD Million)
Table 3 Global Carcinoid Syndrome Management Market by End Users 2017-2022 (USD Million)
List of Figures
Figure 1 Research Process
Figure 2 Porters Five Forces Model
Figure 3 Global Carcinoid Syndrome Management Market, By Organs Affected
Continued….
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/2843 .
About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.